SMS Pharmaceuticals Limited
NSE: SMSPHARMA · Pharmaceuticals
Snapshot
Unlock SMS Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
SMS Pharmaceuticals Limited is an Indian manufacturer specialising in the production of active pharmaceutical ingredients (APIs) and intermediates across a broad range of therapeutic categories. The company also provides contract research services and maintains an international presence through product exports.
Business Model
The company generates revenue primarily through the large-scale manufacturing and sale of APIs and pharmaceutical intermediates to global markets. Additionally, it leverages its technical expertise to provide contract research and development services to the pharmaceutical industry.
- Incorporation Year:1987
Growth Outlook
Growth is driven by the expansion of its diverse API portfolio and the scaling of contract research activities. The company continues to focus on international market penetration to enhance its export revenue streams.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, where non-compliance could lead to export bans or facility restrictions.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and chemical intermediates can significantly impact operating margins.
- Foreign Exchange Risk. As an exporter, the company is exposed to currency fluctuations which may affect the competitiveness and profitability of its international sales.
- Intense Sector Competition. The API manufacturing sector is highly competitive, with pricing pressures from global generic manufacturers impacting long-term profitability.
Start your research today
Unlock AI insights, financials, peers and live data on SMS Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹898 Cr
TTM · consolidated
NET PROFIT
₹102 Cr
TTM · consolidated
EPS
₹11.24
TTM · consolidated
RETURN ON EQUITY
14.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.5%
TTM · consolidated
P/E
34.9x
Q1 FY27 · consolidated
EV/EBITDA
21.9x
Q1 FY27 · consolidated
EBITDA MARGIN
20.3%
TTM · consolidated
NET PROFIT MARGIN
10.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.5x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
SMS Pharmaceuticals LimitedSMSPHARMA | ₹3,676 Cr | 34.92 | 21.91 | 10.2% | 20.3% | 14.4% | 15.5% | +68.3% |
Novartis IndiaNOVARTIND | ₹4,066 Cr | 43.62 | 30.20 | -0.5% | 37.5% | 11.7% | 16.1% | +76.7% |
Aarti Drugs LimitedAARTIDRUGS | ₹3,940 Cr | 20.62 | 13.41 | — | 12.6% | 13.1% | 14.5% | -9.0% |
Zota Health Care LimitedZOTA | ₹3,922 Cr | -36.05 | 339.89 | 78.9% | 1.9% | -22.7% | -14.6% | -14.6% |
Unichem Laboratories LimitedUNICHEMLAB | ₹3,874 Cr | 15.32 | 16.60 | 8.5% | 11.1% | 9.8% | 11.9% | +9.7% |
Kwality Pharmaceuticals LimitedKPL | ₹3,409 Cr | — | — | — | 24.0% | — | — | +253.2% |
As of Q1 FY27
Financials
SMS Pharmaceuticals Limited
NSE: SMSPHARMA · Pharmaceuticals
Snapshot
Unlock SMS Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
SMS Pharmaceuticals Limited is an Indian manufacturer specialising in the production of active pharmaceutical ingredients (APIs) and intermediates across a broad range of therapeutic categories. The company also provides contract research services and maintains an international presence through product exports.
Business Model
The company generates revenue primarily through the large-scale manufacturing and sale of APIs and pharmaceutical intermediates to global markets. Additionally, it leverages its technical expertise to provide contract research and development services to the pharmaceutical industry.
- Incorporation Year:1987
Growth Outlook
Growth is driven by the expansion of its diverse API portfolio and the scaling of contract research activities. The company continues to focus on international market penetration to enhance its export revenue streams.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, where non-compliance could lead to export bans or facility restrictions.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and chemical intermediates can significantly impact operating margins.
- Foreign Exchange Risk. As an exporter, the company is exposed to currency fluctuations which may affect the competitiveness and profitability of its international sales.
- Intense Sector Competition. The API manufacturing sector is highly competitive, with pricing pressures from global generic manufacturers impacting long-term profitability.
Start your research today
Unlock AI insights, financials, peers and live data on SMS Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹898 Cr
TTM · consolidated
NET PROFIT
₹102 Cr
TTM · consolidated
EPS
₹11.24
TTM · consolidated
RETURN ON EQUITY
14.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.5%
TTM · consolidated
P/E
34.9x
Q1 FY27 · consolidated
EV/EBITDA
21.9x
Q1 FY27 · consolidated
EBITDA MARGIN
20.3%
TTM · consolidated
NET PROFIT MARGIN
10.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.5x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27